Drug Profile
Research programme: antibody recruiting molecules - Allied Bristol Life Sciences/Yale University
Alternative Names: ARMs - Allied Bristol Life Sciences/Yale UniversityLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Yale University
- Developer Allied-Bristol Life Sciences
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Prostate-cancer in USA
- 27 Aug 2015 Allied-Bristol Life Sciences acquires the worldwide license to develop antibody-recruiting molecules from Yale University
- 27 Aug 2015 Early research in Prostate cancer in USA (unspecified route)